RCMI Coordinating Center (RCMI CC) Header Logo

Corrigendum to "Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension" [Eur. J. Pharmacol. 943 (2023) 175558].

Abdulkareem AO, Tiwari P, Lone ZR, Iqbal H, Gupta S, Jha RK, Chanda D, Jagavelu K, Hanif K. Corrigendum to "Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension" [Eur. J. Pharmacol. 943 (2023) 175558]. Eur J Pharmacol. 2023 Jul 05; 950:175750.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support